Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rahul Loungani

Advanced Heart Failure and Transplant Cardiology Atlanta, GA Medical Doctor

NPI 1295167955 CMS profile 9165674

95 Collier Rd Nw Ste 3000, Atlanta, GA 30309

Open in the dashboard

General payments

$51,402

285 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$169,869 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Rahul Loungani of Atlanta, GA is reported in the CMS Open Payments database as having received $51,402 across 285 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $169,869 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,364 112
2024 General $9,517 82
2023 General $7,087 48
2022 General $759 31
2021 General $674 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rahul Loungani
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Rahul Loungani were reported at $33,364. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Rahul Loungani Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $0 $863 $224–$4,562 $163
2020 $0 $452 $122–$3,992 $114
2021 $674 $550 $159–$3,571 $132
2022 $759 $729 $221–$4,357 $149
2023 $7,087 $1,002 $309–$5,827 $160
2024 $9,517 $931 $273–$5,204 $164
2025 $33,364 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alnylam Pharmaceuticals Inc. $25,394 47 payments
  2. AstraZeneca Pharmaceuticals LP $21,094 47 payments
  3. Abbott Laboratories $787 15 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $563 17 payments
  5. CVRx, Inc. $502 23 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $453 25 payments
  7. Merck Sharp & Dohme Corporation $384 22 payments
  8. Pfizer Inc. $356 15 payments
  9. BridgeBio Pharma, Inc. $286 13 payments
  10. E.R. Squibb & Sons, L.L.C. $245 12 payments
  11. Other $1,337 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,778 15 payments
  2. Consulting Fee $8,398 6 payments
  3. Food and Beverage $6,857 250 payments
  4. Travel and Lodging $4,162 13 payments
  5. Education $208 1 payment
Products named General payments · program years 2021–2025
  1. AMVUTTRA $24,943 32 payments
  2. FARXIGA $8,127 13 payments
  3. WAINUA $6,247 14 payments
  4. LifeVest $563 17 payments
  5. VERQUVO $519 30 payments
  6. Barostim Neo System $502 23 payments
  7. ONPATTRO $382 12 payments
  8. VYNDAQEL $340 14 payments
  9. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $314 7 payments
  10. Attruby $286 13 payments
  11. Other $2,620 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,838

Median for Cardiology: 2,533

Drug cost

$3,026,091

Median for Cardiology: $485,213

Branded share of claims

32.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 58 $1,808,677
Vyndaqel Tafamidis Meglumine Brand 31 $682,018
Entresto Sacubitril/Valsartan Brand 201 $235,896
Eliquis Apixaban Brand 70 $76,318
Farxiga Dapagliflozin Propanediol Brand 52 $67,491
Jardiance Empagliflozin Brand 48 $65,992
Voriconazole Generic 29 $21,213
Tacrolimus Generic 34 $18,970
Tradjenta Linagliptin Brand 16 $12,771
Mycophenolic Acid Mycophenolate Sodium Brand 13 $7,903

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$107,559

Medicare's payments for the services billed

Medicare patients

281

Average age 72

Services billed

1,311

113 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 72%
Chronic kidney disease 72%
Atrial fibrillation 64%
Diabetes 52%
Arthritis 46%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $3,505
$3,505 52 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $1,323
$1,323 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $221
$221 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $180
$180 48 —
VYNDAQEL
  • PFIZER INC. $147
$147 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record